Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Role of Kupffer cells in the progression of CRC liver metastases after the first stage of ALPPS.

García-Pérez R, Ferrer Fábrega J, Varona-Bosque A, Martínez CM, Revilla-Nuin B, Cabellos L, Pena R, Vilana R, Gonzalez-Abós C, García-Valdecasas JC, Fuster Obregón J.

Sci Rep. 2018 May 24;8(1):8089. doi: 10.1038/s41598-018-26082-4.

2.

Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.

Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM.

J Hepatol. 2017 Dec;67(6):1222-1231. doi: 10.1016/j.jhep.2017.08.013. Epub 2017 Aug 24.

PMID:
28843658
3.

Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.

Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé M, Domingo-Domenech J, Villanueva A, Llovet JM.

Gut. 2017 Mar;66(3):530-540. doi: 10.1136/gutjnl-2015-309501. Epub 2015 Dec 11.

4.

TRUFA: A User-Friendly Web Server for de novo RNA-seq Analysis Using Cluster Computing.

Kornobis E, Cabellos L, Aguilar F, Frías-López C, Rozas J, Marco J, Zardoya R.

Evol Bioinform Online. 2015 May 24;11:97-104. doi: 10.4137/EBO.S23873. eCollection 2015.

5.

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM.

Nat Commun. 2015 Jan 22;6:6087. doi: 10.1038/ncomms7087.

6.

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM.

Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.

7.

Cuckoo search with Lévy flights for weighted Bayesian energy functional optimization in global-support curve data fitting.

Gálvez A, Iglesias A, Cabellos L.

ScientificWorldJournal. 2014;2014:138760. doi: 10.1155/2014/138760. Epub 2014 May 28.

8.

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.

Clin Cancer Res. 2012 Sep 15;18(18):4997-5007. Epub 2012 Jul 18.

9.

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM.

J Hepatol. 2012 Jun;56(6):1343-50. doi: 10.1016/j.jhep.2012.01.009. Epub 2012 Feb 6.

10.

Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2011 Dec;55(6):1325-31. doi: 10.1016/j.jhep.2011.02.034. Epub 2011 Apr 13.

11.

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM.

Gastroenterology. 2011 May;140(5):1618-28.e16. doi: 10.1053/j.gastro.2011.02.009. Epub 2011 Feb 13.

12.

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM.

J Hepatol. 2010 Apr;52(4):550-9. doi: 10.1016/j.jhep.2010.01.015. Epub 2010 Feb 13.

13.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2009 Oct;51(4):725-33. doi: 10.1016/j.jhep.2009.03.028. Epub 2009 Jun 12.

14.

Identification of a novel cyclin required for the intrinsic apoptosis pathway in lymphoid cells.

Roig MB, Roset R, Ortet L, Balsiger NA, Anfosso A, Cabellos L, Garrido M, Alameda F, Brady HJ, Gil-Gómez G.

Cell Death Differ. 2009 Feb;16(2):230-43. doi: 10.1038/cdd.2008.145. Epub 2008 Oct 17.

Supplemental Content

Loading ...
Support Center